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Objective—Angiotensin peptides play a central role in cardiovascular physiology and pathology. Among these peptides,
angiotensin II (Ang II) has been investigated most intensively. However, further angiotensin peptides such as Ang 1-7,
Ang III, and Ang IV also contribute to vascular regulation, and may elicit additional, different, or even opposite effects
to Ang II. Here, we describe a novel Ang II-related, strong vasoconstrictive substance in plasma from healthy humans
and end-stage renal failure patients.
Methods and Results—Chromatographic purification and structural analysis by matrix-assisted laser desorption/ionisation
time-of-flight/time-of-flight (MALDI-TOF/TOF) revealed an angiotensin octapeptide with the sequence Ala-Arg-Val-
Tyr-Ile-His-Pro-Phe, which differs from Ang II in Ala1 instead of Asp1. Des[Asp1]-[Ala1]-Ang II, in the following
named Angiotensin A (Ang A), is most likely generated enzymatically. In the presence of mononuclear leukocytes, Ang
II is converted to Ang A by decarboxylation of Asp1. Ang A has the same affinity to the AT1 receptor as Ang II, but
a higher affinity to the AT2 receptor. In the isolated perfused rat kidney, Ang A revealed a smaller vasoconstrictive effect
than Ang II, which was not modified in the presence of the AT2 receptor antagonist PD 123319, suggesting a lower
intrinsic activity at the AT1 receptor. Ang II and Ang A concentrations in plasma of healthy subjects and end-stage renal
failure patients were determined by matrix-assisted laser desorption/ionisation mass-analysis, because conventional
enzyme immunoassay for Ang II quantification did not distinguish between Ang II and Ang A. In healthy subjects, Ang
A concentrations were less than 20% of the Ang II concentrations, but the ratio Ang A / Ang II was higher in end-stage
renal failure patients.
Conclusion—Ang A is a novel human strong vasoconstrictive angiotensin-derived peptide, most likely generated by
enzymatic transformation through mononuclear leukocyte-derived aspartate decarboxylase. Plasma Ang A concentra-
tion is increased in end-stage renal failure. Because of its stronger agonism at the AT2 receptor, Ang A may modulate
the harmful effects of Ang II. (Arterioscler Thromb Vasc Biol. 2007;27:297-302.)
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The octapeptide, angiotensin II (Ang II) is generally acceptedto play a central role in the physiology and pathology of
vascular regulation. The secular therapeutic success of ACE
inhibitors and AT1 blockers as cardiovascular protective drugs
further underscored the role of Ang II in the pathophysiology of
atherosclerosis and hypertension. Further peptides of the angio-
tensin family, including angiotensins III and IV and angiotensin
1-7 are less well characterized.1,2 These peptides have additional
or antagonizing effects when compared with Ang II.3
Angiotensin 1-7 has been shown to be a vasodilator.4 Similarly,
angiotensin IV is an agonist to the AT4 receptor mediating vasodi-
lation.5 These various angiotensin peptides may gain growing
importance as on ACE inhibition increased amounts of other
angiotensin peptides are formed via ACE-independent pathways.6
To identify novel vasoconstrictive peptides, we screened chro-
matographic fractions obtained from human plasma for vasocon-
strictive effects using the isolated perfused rat kidney as a bioassay.
Methods
Controls, Patients, and Isolation of Plasma
Details of the characteristics of patients and controls are given in the
Table and in the supplemental Methods (available online at http://
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atvb.ahajournals.org). We obtained peripheral blood (10 mL) by
catheterization of the cubital vein and collected the blood in tubes
containing K2-EDTA (7.2 mg). The blood samples were centrifuged
at 300g for 30 minutes at 4°C for isolation of plasma. The resulting
plasma was fractionated by chromatography (see supplemental
Methods).
Analytic Methods
For analytical purposes, samples were submitted to size-exclusion
and reversed phase chromatography and mass-spectrometry (see
supplemental Methods).
Measurements of Perfusion in the Isolated
Perfused Rat Kidney
The effects of aliquots of lyophilized fractions of the analytic
reversed-phase chromatography on vascular tone were evaluated in
an isolated rat kidney perfused at a constant flow rate while perfusion
pressure was continuously monitored. Details of the preparation and
the perfusion procedure are described elsewhere7,8 and in the
supplemental Methods. The underlying substance of the fraction
with a vasoconstrictive effect was identified by matrix-assisted laser
desorption/ionisation time-of-flight/time-of-flight (MALDI-TOF/
TOF) mass-spectrometry (see supplemental Methods).
Preparation and Incubation of Mononuclear
Leukocytes With Ang II and Angiotensinogen
Mononuclear leukocytes were obtained from healthy subjects ac-
cording to established techniques9 (see supplemental Methods). To
test whether Ang A is synthesized out of Ang II in the presence of
mononuclear leukocytes 106 mmol/L AT-II and angiotensinogen,
respectively, were added to the supernatant. After 0, 0.2, 0.5, 1, and
3 hours, aliquots of the supernatant were analyzed by MALDI mass
spectrometry. The incubation with Ang II was repeated with ther-
mically denatured mononuclear leukocytes. For this, mononuclear
leukocytes were heated at 100°C for 10 minutes in a reaction vial.
Cell Culture, Transfection Method, and Membrane
Preparation for Receptor Binding Studies
Details of the cell culture are given in the supplemental Methods.
HEK 293 cells expressing either the AT1- or AT2-receptor protein
were grown on 100-mm Petri dishes, washed twice with 5 mL of
PBS (137 mmol/L, NaCl, 2.7 mmol/L KCl, 1.5 mmol/L KH2PO4,
8.0 mmol/L Na2HPO4, pH 7.4), harvested with a rubber policeman,
and centrifuged at 400g for 10 minutes. For receptor binding studies,
HEK 293 membranes were prepared, as described the supplemental
Methods.
125I-Sar1,Ile8-Ang II Displacement Binding Analysis
Membranes (5 g) were incubated in a final volume of 200 L of
Tris/BAME buffer containing 1 mol/L 125I-Sar1,Ile8-Ang II alone or
increasing concentrations of unlabeled ligand (11012 to 1106
mol/L) for 2 hours at 25°C at 300 rpm in a shaking water bath
(supplemental Methods). The values were used for calculations of
the Ki values of unlabeled ligands (see supplemental Methods).
Ca2-Fluorescent Image Plate Reader Assay
Calcium was measured in VSMCs as previously published.10 The
method is described in the supplemental Methods.
Quantification of Ang and Ang II
Ang A and Ang II was quantified by a MALDI-MS based method as
recently described.11 The supernatants of mononuclear leukocytes
after incubation with Ang II were directly quantified (see supple-
mental Methods).
Quantification of Ang II in Presence and Absence
of Ang A by Enzyme Immunoassay
The “angiotensin II enzyme immunoassay kit” of SpiBio (Socie´te´ de
Pharmacologie et d’Immunologie, Massy, France) was used to test
the cross-reactivity between Ang A and Ang II with a conventional
enzymatic immunoassay used for Ang II-determinations (see sup-
plemental Methods).
Impact of Ang A on Blood Pressure in Angiotensin
II Receptor AT1A Knockout Mice
In these experiments, wild-type mice were compared with angioten-
sin II receptor AT1A KO mice, which had been bred as previously
described by Ito et al12 (see supplemental Methods).
Results
Human plasma was first fractionated by size-exclusion chro-
matography. A typical size-exclusion chromatogram is shown
in Figure 1A. Each fraction obtained from the size-exclusion
step was tested for vasoactivity in the isolated perfused rat
kidney. One of the fractions showing a strong vasoconstric-
tive effect is labeled by an arrow in Figure 1A. This fraction
was chromatographed by reversed-phase chromatography
(Figure 1B). The reversed-phase chromatography allowed on
the one hand to further fractionate the eluate, and on the other
hand to desalt the eluate of the size-exclusion
chromatography.
The fractions obtained from each reversed phase chroma-
tography elution step were tested for vasoconstrictive prop-
erties in the isolated perfused rat kidney. The vasoconstrictive
fraction detected using the isolated perfused kidney is again
indicated by an arrow in Figure 1B. The insert of Figure 1B
shows the vasoconstrictive effect of the labeled fraction.
Clinical and Biochemical Characteristics of Control Subjects and End-Stage Renal
Failure Patients
Healthy Subjects
(n7)
End-Stage Renal Patients
(n7) P Value
Age, years 637 663 n.s.
Sex, m/f 4/3 4/3 n.s.
Blood pressure (systolic/diastolic), mm Hg 1175/663 1326/745 n.s.
Red blood cells, 106l1 4.30.3 3.40.3 n.s.
White blood cells, 103/L 7.40.7 9.91.6 n.s.
Platelets, 103/L 26644 25051 n.s.
Serum creatinine, mol/L 83.35.5 503.369.5 0.01
Blood urea nitrogen, mmol/L 5.50.5 18.91.4 0.01
Values are meanSEM.
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Mass-spectrometric analysis of the underlying substance
by MALDI-TOF revealed a mass peak at m/z 1002.54 (Figure
1C) corresponding to the peptide Ala-Arg-Val-Tyr-Ile-His-
Pro-Phe, as confirmed by tandem MS (MALDI-TOF/TOF).
In particular, the presence of alanine in the N-terminal
position was obtained from the N-terminal b ions as shown in
Figure 1D. The difference in the identified amino acid
sequence compared with that of angiotensin II is given in
Figure 1E in bold.
No DNA sequence code for des[Asp1]-[Ala1]-Ang II,
which in the following will be named Angiotensin A (where
A stands for alanine) or Ang A, was found in data-bases
covering the human genome. Therefore, we addressed the
question, whether Ang A may arise from Ang II by decar-
boxylation of Asp. Although a number of tissues may be
likely candidates for this transformation, we first tested
human mononuclear leukocytes. During the incubation of
lipopolysaccharide (LPS)-activated mononuclear leukocytes
in the presence of Ang II a significant increase in Ang A
levels in the supernatant was detected. The amount of Ang A
and Ang II in the supernatant is quantified in Figure 1F
(relative to internal standard corticotropin [ACTH]). The
synthesis and release of Ang II by mononuclear leukocytes
was recently described.11 LPS-stimulation enhanced the Ang
II conversion, but mononuclear leukocytes also converted
Ang II without LPS-stimulation (rel. mass-signal intensity
[AU] 0.030.01 versus 0.0070.009; n3). No increase in
Ang A levels were detected with intact mononuclear leuko-
cytes in the absence of Ang II nor when a denatured
mononuclear leukocyte preparation was used (data not
shown). During incubation of LPS-activated mononuclear
leukocytes in the presence of renin substrate or angioten-
sinogen, significant increases in Ang A, Ang II, and Ang I
levels in the supernatant, but no mass-signal of a modified
des[Asp1]-[Ala1]-Ang I were detected (data not shown).
Therefore, a modified angiotensinogen is to be excluded as a
source of Ang A.
These experiments suggest that Ang A is not derived from
a precursor protein like angiotensinogen nor modified angio-
tensinogen, but is generated from Ang II by enzymatic
decarboxylation involving mononuclear leukocytes. A non-
enzymatic decarboxylation was excluded by the finding that
after heat-denaturing Ang A synthesis is abolished.
After isolation of Ang A from human plasma, we analyzed
the vasoconstrictive action of this novel peptide in the
isolated perfused rat kidney model. In this model, Ang A
caused a dose-dependent vasoconstriction, which was 90% of
the maximal effect induced by Ang II (Figure 2A). The effect
induced by Ang A was abolished in the presence of the
angiotensin-receptor antagonist AT1 EXP 3174. The EC50
value (mol/L) of Ang A induced vasoconstriction
([4.431.95]107) was an order of magnitude lower than
Figure 1. A, Size-exclusion chromatogram of
human plasma (conditions: Sephacryl S-100 high-
resolution, Pharmacia BioTech, Sweden; column
dimension: 100016 mm; eluent: 0.9% NaCl in
water; flow rate: 1.0 mL/min; abscissa: retention
time [h]; ordinate: UV-absorption at 280 nm [arbi-
trary units]). The arrow indicates a fraction with
strong vasoconstrictive properties on testing in the
isolated perfused rat kidney. B, Reversed phase
chromatography of the size-exclusion fraction
labeled by an arrow in A using an analytical
reversed-phase high performance liquid chro-
matographic column (conditions: Chromolith Per-
formance [1004.6 mm ID], Merck, Darmstadt,
Germany; eluent A: 0.1% trifluoroacetic acid in
water; eluent B: 0.1% trifluoroacetic acid in water-
acetonitrile [20:80, v/v-%]; gradient: 0 to 2 min-
utes: 0% eluent B, 2 to 32 minutes: 0% to 75%
B, 32 to 32.5 minutes: 75% to 100% eluent B;
32.5 to 33.5 minutes: 100% B; flow rate: 2.0
mL/min; abscissa: retention time [min]; ordinate:
UV-absorption at 280 nm [arbitrary units]). The
inset shows the effect of the labeled fraction on
the perfusion pressure of the isolated perfused rat
kidney. C, MALDI-TOF mass spectrum of the va-
soconstrictive substance isolated by RP-HPLC.
The peak with a m/z ratio of 1002.54 (calculated
m/z 1002.55) corresponds to peptide sequence
Ala-Arg-Val-Tyr-Ile-His-Pro-Phe. D, MALDI-TOF/
TOF-MS/MS spectrum of the peak with m/z
1002.54 shown in C. Relevant ions are labeled
according to the accepted nomenclature. Both the
b ions and the y ions confirm the amino acid
sequence of des [Asp1]-[Ala1]-Ang II (Ang A). E,
Amino acid sequence of Ang A (bold: Difference
from the amino acid sequence of angiotensin II).
F, Quantification of Ang A (E) and Ang II () in
supernatants from mononuclear leukocytes after
incubation with Ang II (relative to internal standard
ACTH).
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that of Ang II-mediated vasoconstriction ([5.202.52]108). The
AT2 receptor antagonist PD123319 had no significant effect on the
vasoconstriction induced by Ang A.
Thus, Ang A revealed a lower vasoconstrictive potency
and efficacy than Ang II, suggesting that it acts only as a
partial agonist. Accordingly, Ang A was less active than Ang
II in an in vivo assay (Figure 2B). Increasing concentrations
of the peptides were injected into the femoral vein of
wild-type and Ang II AT1A receptor–deficient mice, and the
blood pressure changes were monitored by a femoral artery
catheter. Both peptides induced a strong hypertensive re-
sponse, but Ang A only at 10 times higher concentrations
than Ang II. Both peptides signal via the AT1A receptor,
because the blood pressure response was blunted in knockout
animals (Figure 2B). The kinetics of response to Ang A and
Ang II application were comparable in this set-up (Figure
2C).
To elucidate whether the lower potency of the vasocon-
striction induced by Ang A could be attributed to a lower
affinity of Ang A to the AT1 receptor than that of Ang II,
and/or to a higher affinity to the AT2 receptor, binding of Ang
A and Ang II to AT1 and AT2 receptors expressed in human
embryonic kidney (HEK) 293 cells was studied. We charac-
terized the receptor binding of both peptides by displacement
of the radioligand [125I]-Sar,1 Ile8 angiotensin II by increasing
concentrations of unlabeled Ang II and Ang A (Figure 3A and
3B). IC50-values of the rat AT1-receptor (Figure 3A) and the
rat AT2-receptor (Figure 3B) were [-log IC50] 9.540.04 and
9.920.04 for Ang A, and [-log IC50] 9.490.06 and
9.590.04 for Ang II. Whereas no significant difference in
the affinity of AT1 receptors for Ang A and Ang II was
observed (Figure 3A), the affinity of AT2 receptors for Ang A
was significantly higher than for Ang II (Figure 3B). VSMCs
stimulated with Ang II or Ang A showed an dose-dependent
increase in cytosolic calcium with a significant difference
within their EC50 values ([-log mol/L] Ang II: 7.70.1 and
Ang A: 7.00.1, P0.05, n5 independent experiments;
Figure 3C). In the presence of EXP3174 (1 mol/L) cytosolic
calcium increase by half-maximal agonistic concentration of
Ang II (10 nmol/L) or Ang A (100 nmol/L) was completely
inhibited (Figure 3D). These data suggest that the lower
potency of Ang A to induce vasoconstriction is caused neither
by a lower affinity to AT1 receptors nor by higher activity at
the AT2 receptor, but due to a lower intrinsic activity at the
AT1 receptor.
Next we quantified the Ang A/Ang II ratio in human
plasma by MALDI mass spectrometry. As shown in Figure
3E, the Ang A/Ang II ratio was higher in end-stage renal
failure patients than in healthy subjects. Measurements in
seven healthy subjects revealed an Ang A concentration of
6.74.7 pg/mL, which is 9.73.3% (calculated for each
patient; min.: 2.1%; max.: 25.2%) of the Ang II concentration
found in the same subjects (88.012.3 pg/mL). The Ang A
concentration was increased in plasma of end-stage renal
failure patients (n7) to 28.411.0 pg/mL; this corresponds
to 30.99.1% (calculated for each patient; min.: 5.1%; max.:
73.6%; P0.05) of the Ang II concentration found in the
same patients (127.529.4 pg/mL).
A conventional enzyme immunoassay for Ang II quantifi-
cation did not distinguish between Ang II and Ang A (Figure
3F).
Discussion
Ang A is a novel angiotensin peptide, which is present in
human plasma; it is derived from Ang II by enzymatic
decarboxylation, emphasizing the physiological importance
of Ang A. A yet unknown decarboxylase present in human
mononuclear cells is one potential cellular source of Ang A.
At present, the nature of this decarboxylase, its substrate
specificity, and its tissue distribution are unknown. It remains
Figure 2. A, Change in perfusion pressure in the isolated per-
fused rat kidney induced by Ang A (E), Ang II (F), and Ang A in
the presence of angiotensin-receptor antagonist AT1 EXP 3174
() or in the presence of angiotensin-receptor antagonist AT2
PD 123319 3174 (itriaf) (abscissa: agonist [log mol/L]; ordinate:
change in perfusion pressure [mm Hg]). MeansSEM, n6. B,
Rise in mean arterial blood pressure in Angiotensin II receptor
AT1A knockout (filled symbols) mice and in wild-type mice
(open symbols) after injection of Ang A (F/E) and Ang II (f/).
Maximal increase was detected 10 to 40 sec after injection.
(abscissa: concentration of agonist [g/kg body weight); ordi-
nate: change in mean arterial pressure [mm Hg]). MeansSEM,
n6. C, Alteration of mean arterial blood pressure in wild-type
mice after injection of Ang A (E/F) and Ang II (/f) (open sym-
bols: 100 ng/kg body weight; filled symbols: 1 g/kg body
weight; abscissa: time after injection concentration of agonist
[sec]; ordinate: change in mean arterial pressure [mm Hg]).
MeansSEM, n6.
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to be shown whether other cells or tissues may also contribute
to Ang A formation.
The Ang A/Ang II ratio in plasma of healthy subjects was
below 0.2 in all, but this ratio increased to up to 0.7 in patients
with stage 5 chronic kidney disease. The increased Ang
A/Ang II ratio in patients with stage 5 chronic kidney disease
may either indicate an increased activity of decarboxylase in
human mononuclear cells from patients with chronic kidney
disease stage 5, a reduced enzymatic degradation of Ang A in
these patients, or renal excretion. An increase of the Ang A
half-life is not unlikely, because modifications of half life of
low molecular proteins or peptides in chronic renal failure
patients are described frequently (eg,13,14). Presently it is
unknown whether the increased Ang A/Ang II ratio in plasma
may be related to well-known uremic complications in
patients with chronic kidney disease stage 5. Conventional
enzyme immunoassays do not distinguish between Ang II and
Ang A; these assays quantify the sum of Ang II and Ang A.
Interestingly, the affinity of Ang A to the AT1 receptor is
nearly equal to that of Ang II. However, the potency to induce
vasoconstriction is lower than that of Ang II. Thus, Ang A is
a less potent, and only partial agonist at the AT1 receptor.
This potential partial agonism will be the more effective in
subjects with an increased Ang A/Ang II ratio. It is notable
that Ang III, which lacks the amino-terminal aspartate resi-
due, has a similar affinity to the AT1 receptor as Ang A. In
contrast to Ang A, for Ang III the same biological activity as
for Ang II has been demonstrated.15 In addition, Ang II and
Ang III cause a similar vascular effect when injected intra-
cerebroventricularly or directly into certain brain regions.16,17
In the case of Ang II the increase in blood pressure can be
inhibited by a selective inhibitor of aminopeptidase A (APA),
which mediates the generation of Ang III by the cleavage of
the N-terminal aspartate residue of Ang II.18 These data
suggest that the vasoconstrictive effect of Ang II is mediated
by Ang III. Whether Ang III provokes an increase in blood
pressure and release of plasma arginine-vasopressin (arginine
vasopressin) through the activation of AT1 and/or AT2 recep-
tors or a yet unidentified effector molecule is still not clear.19
In the case of Ang A, the processing to Ang III could be
impaired, because the APA has a preference for N-terminal
acidic residues such as aspartate or glutamate. Therefore, it is
intriguing to speculate that decarboxylation of aspartate in
Ang II may prevent or delay Ang III formation.
Interestingly, the affinity of Ang A to the AT2 receptor is
higher than that of Ang II. Whether the intrinsic activity of
Ang A at the AT2 receptor also translates into an increase in
intrinsic activity requires a suitable model to study AT2-
mediated signaling events. For example, the mechanisms by
which the AT2 receptor mediates vasodilation and which
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Figure 3. A, Displacement of [I125] Sar,1 Ile8
angiotensin II by Ang A (E) and Ang II (F) in
HEK 293 cells transiently transfected with
AT1-receptors. MeansSEM, n5 in dupli-
cate. There was no significant difference
between Ang A and Ang II. B, Displacement
of [I125] Sar,1 Ile8 angiotensin II by Ang A (E)
and Ang II (F) in HEK 293 cells transiently
transfected with AT2 receptors.
MeansSEM, n5 in duplicate; *P0.05;
**P0.01, Ang A versus Ang II. C, VSMCs
were loaded with Fluo4-AM for 60 minutes
and stimulated with increasing concentration
of Ang A (E) or Ang II (F) for 5 minutes. The
peak values in fluorescence emission
obtained for the different agonist concentra-
tions were normalized to the maximal
response. (ordinate: relative light units; %;
MeansSEM, n5 in triplicates; **P0.01,
Ang A versus Ang II). D, VSMCs were
loaded with Fluo4-AM for 30 minutes and
stimulated with half-maximal agonistic con-
centration of Ang II (10 nmol/L) or Ang A
(100 nmol/L) for 5 minutes in the absence
(f) of presence of EXP 3174 (1 mol/L)3 or
PD123319 (1 mol/L; ). Both Ang II or Ang
A induced calcium increase in these cells.
The peak values in fluorescence emission
obtained were normalized to the responses
without agonists. MeansSEM, n4 in trip-
licates. E, Mass-spectrometry-based deter-
mination of Ang A/Ang II ratio in plasma of
healthy control subjects (E; right y-axis) and
end-stage renal failure patients (F; left
y-axis) (meanSEM, n7, single values and
means; P0.05). F, Quantification of syn-
thetic Ang A and synthetic Ang II by enzyme
immunoassay (concentrations used in the
assay are given in pmol/L in the corre-
sponding bars; each n5).
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signaling pathways are involved remain obscure. Several
authors favor an indirect mechanism, such as stimulation of
the B2 bradykinin receptor, possibly via an intracellular
acidification and resulting in an increased NO and cGMP
production.20,21 Furthermore, there are reports suggesting that
phosphotyrosine activity is increased after AT2 receptor
stimulation.22–24 Further elucidation of AT2 receptor signaling
potentially will help to study the downstream effects of Ang
A binding to AT2 receptor. Our data demonstrate that Ang-A
represents a new metabolite of Ang II system, which is the
first one acting as a partial agonist. Further studies will be
required to analyze whether this new peptide reveals altered
metabolism to Ang III and Ang IV peptides, thereby adding
to the complexity of the regulation of the cardiovascular
system.
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SUPPLEMENTARY METHODS 
CHEMICALS 
HPLC water (gradient grade) and acetonitrile were purchased from Merck (Darmstadt, 
Germany), all other substances from Sigma-Aldrich (Munich, Germany). 
 
CONTROLS AND PATIENTS 
Details of the characteristics of patients and controls are given in Table 1. A total of 7 
patients with stage 5 chronic kidney disease (4 males, 3 females; mean age 66 ± 3 years) who 
were on regular hemodialysis were investigated. Written informed consent was obtained from 
each patient and ethical approval by the local ethics committee was obtained for the study. 
The cause of chronic kidney disease stage 5 was diabetic nephropathy in two cases, 
nephrosclerosis in 2 cases, polycystic kidney disease in one case and unknown in two cases. 
One patient was on angiotensin converting enzyme inhibitors, two on ß-blockers, two on 
calcium channel blockers, and four on erythropoietin therapy. None of the patients was a 
smoker.  
 
Mean duration of hemodialysis at inclusion was 27 ± 11 months. All patients were routinely 
dialyzed for 4 hours three times weekly using biocompatible membranes with no dialyzer 
reuse. Dialyses were performed using standardized techniques with bicarbonate-based 
dialysates and controlled ultrafiltration rate. Blood flow rates were 250 to 300 mL/min, 
dialysate flow rates were 500 mL/min, dialysate conductivity was 135 mS. Mean kt/V (the 
amount of plasma cleared of urea divided by the urea distribution volume) was 1.1 ± 0.1 in 
single pool. Patient dry body weight was defined as the body weight below, which a normal 
albuminemic patient experiences hypotension or muscle cramps and postural hypotension is 
clinically manifest. The mean dry weight was 73 ± 5 kg. Blood pressure was measured 
predialysis with a sphygmomanometer after 10 minutes of recumbency. Phases I and V of the 
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Korotkoff sounds were taken as the systolic and diastolic blood pressure, respectively. Mean 
systolic blood pressure was 132 ± 6 mmHg and mean diastolic blood pressure was 74 ± 5 
mmHg. Heart rate was 74 ± 5 mmHg. 
 
 
SIZE-EXCLUSION CHROMATOGRAPHY 
We directly fractionated the human plasma by size-exclusion-chromatography. For this, we 
equilibrated the size-exclusion chromatography gel (Sephacryl S-100 High Resolution; 
1000 x 16 mm, S100 HR, Pharmacia BioTech, Uppsala, Sweden) with 0.9% NaCl in water. 
We loaded human plasma onto the column to elute it with 0.9% NaCl in water at a flow rate 
of 1 mL/min. We monitored the elution with a UV-detector at 280 nm. 
 
ANALYTICAL REVERSED-PHASE CHROMATOGRAPHY 
We loaded the eluate onto a monolithic reversed phase chromatography column 
(ChromolithTM Performance; 100 x 4.6 mm I.D., Merck, Darmstadt, Germany). We used 
0.1% trifluoroacetic acid (TFA) in water as an equilibration buffer (flow rate: 2 mL/min). We 
eluted the retained substances using 0.1% trifluoroacetic acid (TFA) in water-acetonitrile 
(20:80, v/v-%) and the following gradient: 0-2 min: 0% eluent B, 2-32 min: 0-75% B, 32-32.5 
min: 75- 100% eluent B; 32.5-33.5 min: 100% B; flow rate: 2.0 mL/min. We monitored the 
elution with a UV-detector at 280 nm. 
 
MEASUREMENTS OF PERFUSION PRESSURE IN THE ISOLATED PERFUSED RAT 
KIDNEY 
The kidney was excised and immediately mounted into the perfusion system. Briefly, the 
isolated rat kidney was perfused by a peristaltic pump in a single-pass system with a solution 
containing 115 mmol/L NaCl, 4.6 mmol/L KCl, 1 mmol/L CaCl2, 1.2 mmol/L MgSO4, 1.2 
mmol/L NaH2PO4, 22 mmol/L NaHCO3, 49 mmol/L glucose and 35 g of gelatine/L 
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(Haemaccel-Behringwerke, Marburg, Germany), and equilibrated with 95% O2/5% CO2. The 
perfusion medium and the kidney were kept constantly at 37°C. Perfusion pressure was 
continuously monitored by a transducer (Gould P23, Oxnard, CA, USA) connected to a 
bridge amplifier (Hugo Sachs, March-Hugstetten, Germany).  
 
Vasoconstrictor responses of the isolated perfused rat kidney to the fractions to be tested were 
assessed after an equilibration period at basal tone of 30 min. When considered relevant the 
angiotensin-receptor antagonist EXP 3174 (1 µmol/L; AT1) or PD 123319 (1 µmol/L, AT2) 
was added to the perfusate 30 min before challenge with the fractions to be tested. 
 
IDENTIFICATION OF THE ISOLATED PEPTIDE BY MASS SPECTROMETRY  
Matrix-assisted laser desorption/ionisation mass spectrometry (MALDI-MS) measurements 
were performed using a Voyager-DE STR BioSpectrometry Workstation mass spectrometer 
(Perspective Biosystems, Framingham, MA, USA). One mL of the peptide solution was 
mixed with 1 mL of α-cyano-4-hydroxycinnamic acid matrix solution consisting of 10 mg of 
matrix dissolved in 1mL of 0.3% TFA in acetonitrile/water (50:50, v/v-%). From the resulting 
mixture 1 mL was applied to the sample plate. Samples were air-dried at ambient temperature 
(24°C). Measurements were performed in the reflectron mode at an acceleration voltage of 20 
kV, 70% grid voltage and a delay of 150 ns. Each spectrum represented the accumulation of 
250 laser shots. Three spectra of one spot measured at different positions were averaged. 
MS/MS fragment spectra were recorded using a matrix-assisted laser desorption/ionisation 
time-of-flight / time-of-flight (MALDI-TOF/TOF) instrument (4700 Proteomics analyzer, 
Applied Biosystems, Framingham, MA, USA) equipped with an Nd:YAG laser (355 nm) 
operating at a frequency of 200 Hz. Air was used as the collision gas. Spectra were obtained 
by accumulation of up to 20,000 consecutive laser shots. Fragment data were analysed using 
the Data Explorer software (version V5.1; Applied Biosystems, Darmstadt, Germany). 
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PREPARATION OF MONONUCLEAR LEUKOCYTES 
Briefly, 400 mL heparinized blood was drawn by venipuncture from the antecubital vein and 
centrifuged at 240 g for 15 min. After removing the supernatant, mononuclear leukocytes 
were isolated by layering 5 mL diluted blood (50:50 v/v-% with isotonic NaCl) on 3 mL 
Histopaque (Sigma-Aldrich, Munich, Germany; 5:6 w/v-% Ficoll; density 1.077 g/mL) and 
centrifugation at 240 g for 20 min. The mononuclear leukocyte interphase was carefully 
aspirated, washed three times in isotonic NaCl by centrifugation at 400 g for 5 min, and 
resuspended in Hanks’ balanced salt solution containing (in mmol/L): NaCl, 136; KCl, 5.4; 
KH2PO4, 0.44; Na2HPO4, 0.34; CaCl2, 1; D-glucose, 5.6; N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid, 10; pH 7.4. Mononuclear leukocytes were incubated in the absence and 
presence of 10 µg lipopolysaccharide (LPS Serotype 0111:B4 from E. coli). After incubation 
for 60 minutes, mononuclear leukocytes were centrifuged to collect the supernatant. 
 
BINDING STUDIES 
All binding studies were performed as displacement studies. For binding studies of Ang A 
with AT1- and AT2-receptors, HEK 293 cells were transiently transfected with human AT1- 
and AT2-receptors. cDNA encoding the human AT1 (pcDNA3.AT1)- and AT2 
(pcDNA3.AT2)-receptor was kindly provided by Tadashi Inagami (Department of 
Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA). 
 
CELL CULTURE AND TRANSFECTION METHODS  
HEK 293 cells were cultured at 5% CO2 in Dulbecco’s modified Eagle’s medium containing 
10% heat-inactivated fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 
µg/mL). Cells were grown on poly-L-lysine-coated plastic material to improve adherence. For 
a 15-mm-diameter well of a 24-well plate, 5 X 104 HEK 293 cells were transfected with 250 
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ng of plasmid DNA and 2 mL of Lipofectamin according to the supplier’s recommendations. 
After removal of the transfection reagent, cells were incubated for 48 h. 
 
MEMBRANE PREPARATION FOR RECEPTOR BINDING STUDIES 
The pellet was resuspended in Tris-BAME buffer (50 mmol/L Tris, 0.15 mmol/L bacitracin, 
0.0015% aprotinin, 10 mmol/L MgCl2, 2 mmol/L EGTA, pH 7.3), and the suspension was 
homogenized with a glass/Teflon homogenizer (10 strokes), and centrifuged at 26,000 g for 
30 min. The pellet was rehomogenized in Tris-BAME and aliquots of the resulting suspension 
were stored at -70°C until use. 
 
125I-SAR1,ILE8-ANG II DISPLACEMENT BINDING ANALYSIS 
The samples were then transferred onto GF/C filters (Whatman International Ltd., Maidstone, 
UK), pretreated with 0.1 (w/v-%) polyethylenimine and washed rapidly twice with PBS using 
a Brandel cell harvester. Filters were finally transferred into 5 mL vials and radioactivity was 
determined in a liquid scintillation counter. Data were analysed with RadLig software 4.0 
(Cambridge, UK), and graphs were generated with Prism Software 2.02 (GraphPad, San 
Diego, CA). Saturation analysis yielded KD values of 1 µmol/L and 100 nmol/L for the AT1- 
and AT2-receptor. 
 
CALCULATION OF DISPLACEMENT CURVES  
For AT-receptor displacement studies, non-specific binding was accounted for by determining 
the number of counts measured in the presence of 1 µmol/L Sar1, Ile8 Ang II. The values 
obtained were deduced from the total counts to calculate specific binding. Basal values (dpm, 
mean ± S.E.M., n=12 – 15) of 100% binding were 2670 ± 157 (AT1-receptor) and 6015 ± 213 
(AT2-receptor). Specific binding in the sole presence of radioligands was normalized to 
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100%, and the remaining data were corrected to this figure. IC50-values were calculated using 
a non-linear curve fitting function (PrismTM, Graph Pad, San Diego, CA. USA).  
 
Ca2+- FLUORESCENT IMAGE PLATE READER (FLIPR) ASSAY 
VSMCs were loaded with 1 µM FLUO4-/AM and 0.04% Pluronic F-127 (both from 
Molecular Probes, Carlsbad, Ca, USA) in HBSS with 20 mmol/L HEPES and 2.5 mmol/L 
probenecid. After loading, cells were washed twice with HBS by an automated plate washer 
(Denley Cellwash, Labsystems, Helsinki, Finland) and transferred to the FLIPR (Mithras 
LB940, Berthold, Bad Wildungen, Germany). About 50,000 cells were in each well. 10 µl of 
agonists were delivered to the wells containing 100 µl of HBS. Fluorescence emissions from 
the wells were monitored at an emission wavelength of 515 nm and after excitation with 488 
nm. Fluorescence data were collected 60 s before and 5–10 min after stimulation, and 
analysed off-line. 
 
SYNTHESIS OF THE IDENTIFIED PEPTIDE  
The identified peptide was synthesized automatically by the solid-phase method using 
standard Fmoc chemistry in a continuous flow mode. TentaGel S Random-Access Memory 
(RAM) resin 0.21 mmol/g was used for peptide amide synthesis. TentaGel S p-
hydroxybenzoic acid (PHB) resin (Rapp Polymere, Tuebingen, Germany) was used for the 
synthesis of the free acid of urocortin, o-benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBTU), n,n-diisopropylethylamine (DIEA) (condition: coupling 20 
min, deblocking with 20% piperidine in N,N-dimethyl formamide (DMF) for 15 min, final 
cleavage with 95% TFA/5% water for 3 h). Purification of crude peptide was carried out by 
preparative HPLC on PolyEncap A300 (10 µm particle size, 250 mm x 20 mm, Bischoff 
Analysentechnik GmbH, Leonberg, Germany) in water with increasing concentrations of 
acetonitrile (ACN) as mobile phase. An eluent gradient of 5-70 (v/v-%) ACN/water (0.1% 
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TFA) over 70 min with a flow rate of 10 mL/min was used. The purified peptide was 
lyophilized and characterized by MALDI mass spectroscopy as described above using α-
cyano-4-hydroxycinnamic acid and sinapinic acid as matrix and this procedure resulted in the 
same [M + H]+ mass peaks as the genuine product after its direct isolation 1. 
 
QUANTIFICATION OF ANG A AND ANG II  
The adrenocorticotropic hormone (ACTH) fragment 18-39 (Arg-Pro-Val-Lys-Val-Tyr-Pro-
Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe; 10 µg per sample) was 
added as internal standard. Hereby local differences in the peptide concentration on the 
MALDI spot were neutralized. The lyophilised fractions of the reversed-phase 
chromatography of the plasma were resuspended in 10 µL 0.1% TFA before quantification. 
The supernatants of mononuclear leukocytes after incubation with Ang II were directly 
quantified. 1 µL of each fraction was prepared on a prestructured MALDI sample support 
(MTP AnchorChipTM 400/384, Bruker-Daltonics, Bremen, Germany) using the α-4-
hydroxycinnamic acid affinity sample preparation method 2. The mass spectrometric 
measurements were performed on a Bruker Reflex III instrument (Bruker-Daltonics, Bremen, 
Germany). The instrument was equipped with a nitrogen laser (VSL-337 ND, Laser Science, 
USA), emitting at 337 nm. The laser beam was focused to a typical diameter of 50 µm at an 
angle of 45° to the surface of a target. Samples were checked microscopically. On average, 
200 single-shot spectra were accumulated to improve the signal-to-noise ratio. 
 
QUANTIFICATION OF ANG II IN PRESENCE AND ABSENCE OF ANG A BY 
ENZYME IMMUNOASSAY 
The kit was used according to the manufacturer’s protocol 3. Briefly, each well of the plate 
containing immobilised monoclonal anti-Angiotensin II (mAb3 131) 3 was washed five times 
with a washing buffer (0.01 mol/L phosphate with 0.05% Tween 20; pH 7.4). Different 
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aqueous mixtures of Ang A and Ang II (100 µl; 1-100 pg/mL) were distributed over the 
wells. After an incubation time of 1 h, glutaraldehyde (50 µl; 0.5 vol-% in 0.1 mol/L 
phosphate buffer; pH 7.5) was added and the plate was incubated for 5 min at room 
temperature. Next, borane trimethylamine (50 µl in 2 mol/L HCl/MeOH (50/50 vol-%) was 
added for 5 min. After washing five times, an anti-angiotensin II IgG tracer (Société de 
Pharmacologie et Immunologie, BIO, Massy Cedex, France) (100 µl; 5 EU/mL) was added to 
the plate. The plate was incubated overnight at +4°C. After washing five times, 200 µl 
Ellman´s reagent (0.75 mmol/L acetylthiocholine iodide, 14.5 mmol/L NaCl, 25 mmol/L, 
5,5´-dithiobis(2-nitro) benzoic acid, 0.1 mol/L phosphate buffer, pH 7.4) was added. The 
plate was read at 414 nm after 15 min using an automatic microplate reader (Mircoplate-
Reader 3550, BioRad, Munich, Germany). 
 
IMPACT OF ANG A ON BLOOD PRESSURE IN ANGIOTENSIN II RECEPTOR AT1A 
KNOCKOUT MICE 
All animal experiments were performed according to the institutional guidelines of the Max-
Delbrück-Center for Molecular Medicine (Berlin, Germany) and were approved by the local 
authorities. Mice were anaesthetized with Ketavet (Ketaminhydrochlorid) 100 mg/kg + 
Rompun (Xylazinehydrochlorid) 10 mg/kg. Applying aseptic techniques, catheters (4 to 5 cm 
length, 0.25 mm inner diameter, and 0.40 mm outer diameter) were placed in the femoral 
artery for the measurement of arterial pressure and in the femoral vein for infusions with the 
aid of a dissecting microscope. The catheters were filled with sterile 0.9% NaCl solution 
containing heparin (10 U/ml) and tunneled subcutaneously, exteriorized at the back of the 
neck, and sutured in place between the scapulae. The mice were allowed to recover for 72 h 
before the experiment was started. During the recovery period 24-48 h after surgery, catheters 
were flushed with heparinized saline solution (3-5 µl/gbw).  
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On the day of the experiment, mice were tested in a conscious, unrestrained state in their 
home cages. Sixty minutes after the arterial catheter had been coupled with a 23-gauge 
stainless steel pin to a 25-cm piece of Portex polyethylene tubing (PE-50; 0.58 mm inner 
diameter, 0.96 mm outer diameter) to a MLT 1050/D pressure transducer (AD Instruments, 
Colorado Springs, USA), baseline blood pressure and heart rate were measured continuously 
for 1 hour after the coupling. All hemodynamic data were collected and analyzed on a 
computer using Chart software (Version 5; Powerlab; Colorado Springs, USA). 
 
Angiotensin II and Ang A were dissolved in a 0.9% NaCl solution and injected in bolus via 
the venous line in a volume of 1 µl/gbw. Before each experimental infusion, the response to 
vehicle was tested. 
 
STATISTICS 
All data are given as means ± S.E.M. of the individual values. For the displacement 
experiments, Friedman’s test was used to compare means of controls with the binding 
observed in the presence of displacing substances. 
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